Litigation Details for UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)
✉ Email this page to a colleague
UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-03-05 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Referred To | ||
| Patents | 10,130,589 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in UCB, Inc. v. Actavis Laboratories UT, Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-02-06 | 80 | Opinion - Memorandum Opinion | infringement of U.S. Patent No. 10,130,589 (the "' 589 Patent"). (D.I. 1) The patent-in-suit relates…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id at 1321 (internal quotation marks omitted). The patent "specification…of the ' 589 patent, and, thus, should be limiting. See, e.g., ' 589 patent at 3:12-36, 5:22-…preamble term was not relied on during patent prosecution as being patentably significant or to distinguish | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
